Neoadjuvant nivolumab plus ipilimumab in microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) rectal tumors: ECOG-ACRIN EA2201

被引：0
|
作者：
Ciombor, K. K. [1 ]
Hong, S. [2 ]
Eng, C. [3 ]
Yao, X. [4 ]
You, N. [5 ]
Das, P. [6 ]
Chakravarthy, A. [7 ]
O'Dwyer, P. J. [8 ]
机构：
[1] Vanderbilt Univ, Med Ctr, Internal Med Hematol Oncol Dept, Preston Canc Res Bldg, Nashville, TN USA
[2] Dana Farber Canc Inst, Data Sci, Boston, MA USA
[3] Vanderbilt Ingram Canc Ctr, Hematol Oncol Dept, Nashville, TN USA
[4] Cleveland Clin Florida, Oncol, Weston, FL USA
[5] Univ Texas MD Anderson Canc Ctr, Colorectal Surg, Houston, TX USA
[6] Univ Texas MD Anderson Canc Ctr, Radiol Oncol, Houston, TX USA
[7] Vanderbilt Univ, Med Ctr, Radiat Oncol, Nashville, TN USA
[8] ECOG ACRIN Canc Res Grp, Med Oncol Dept, Philadelphia, PA USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.249
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
242MO
引用
收藏
页码：S104 / S104
页数：1
相关论文
共 50 条
  • [1] EA2201: An ECOG-ACRIN phase II study of neoadjuvant nivolumab plus ipilimumab and short course radiation in MSI-H/dMMR rectal tumors
    Ciombor, Kristen Keon
    Hong, Sung Chul
    Eng, Cathy
    Yao, Xin
    Cho, May Thet
    You, Y. Nancy
    Das, Prajnan
    Chakravarthy, Anuradha Bapsi
    O'Dwyer, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Epidemiology of Microsatellite Instability High (MSI-H) and Deficient Mismatch Repair (dMMR) in Solid Tumors: A Structured Literature Review
    Lorenzi, Maria
    Amonkar, Mayur
    Zhang, Jacky
    Mehta, Shivani
    Liaw, Kai-Li
    JOURNAL OF ONCOLOGY, 2020, 2020
  • [3] SAFETY PROFILE OF NIVOLUMAB plus IPILIMUMAB COMBINATION THERAPY IN PATIENTS WITH DNA MISMATCH REPAIR-DEFICIENT/MICROSATELLITE INSTABILITY-HIGH (DMMR/MSI-H) METASTATIC COLORECTAL CANCER (MCRC) IN CHECKMATE-142
    Brutcher, Edith
    Khoukaz, Taline
    Hartman, Leighanne
    ONCOLOGY NURSING FORUM, 2018, 45 (02)
  • [4] Clinicopathological and genomic characteristics of DNA Mismatch Repair-Deficient (dMMR) and microsatellite instability-high (MSI-H) resected gastric adenocarcinoma
    Zhou, J.
    Liang, B.
    Yin, M.
    Zhang, H.
    Liu, F.
    Dong, L.
    Zhang, B.
    Xu, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S921 - S922
  • [5] STRUCTURED LITERATURE REVIEW OF THE PREVALENCE OF MICROSATELLITE INSTABILITY HIGH (MSI-H) AND DEFICIENT MISMATCH REPAIR (DMMR) AMONG SOLID TUMORS
    Lorenzi, M.
    Amonkar, M.
    Zhang, J.
    Mehta, S.
    Liaw, K.
    VALUE IN HEALTH, 2018, 21 : S22 - S23
  • [6] Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients (pts) with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma (OGA): The GERCOR NEONIPIGA phase II study
    Andre, Thierry
    Tougeron, David
    Piessen, Guillaume
    De La Fouchardiere, Christelle
    Louvet, Christophe
    Adenis, Antoine
    Jary, Marine
    Tournigand, Christophe
    Aparicio, Thomas
    Desrame, Jerome
    Lievre, Astrid
    Garcia-Larnicol, Marie-Line
    Pudlarz, Thomas
    Henriques, Julie
    Cohen, Romain
    Lefevre, Jeremie
    Svrcek, Magali
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [7] Pembrolizumab in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors: An update of the phase II KEYNOTE-158 trial
    Maio, M.
    Ascierto, P. A.
    Motola Kuba, D.
    Penel, N.
    Cassier, P. A.
    Bariani, G. M.
    De Jesus-Acosta, A.
    Doi, T.
    Longo Munoz, F.
    Miller, W. H.
    Oh, D-Y.
    Gottfried, M.
    Yao, L.
    Jin, F. J.
    Gozman, A.
    Marabelle, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S589 - S590
  • [8] Nivolumab plus ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142.
    Andre, Thierry
    Lonardi, Sara
    Wong, Mark
    Lenz, Heinz-Josef
    Gelsomino, Fabio
    Aglietta, Massimo
    Morse, Michael
    Van Cutsem, Eric
    McDermott, Raymond S.
    Hill, Andrew G.
    Sawyer, Michael B.
    Hendlisz, Alain
    Neyns, Bart
    Svrcek, Magali
    Moss, Rebecca Anne
    Ledeine, Jean-Marie
    Cao, Z. Alexander
    Kamble, Shital
    Kopetz, Scott
    Overman, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [9] A phase 3 study of nivolumab (NIVO), NIVO plus ipilimumab (IPI), or chemotherapy for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW
    Andre, T.
    Van Cutsem, E.
    Elez, E.
    Bennouna, J.
    de la Fouchardiere, C.
    Yoshino, T.
    Jensen, L.
    Mendez, G.
    Li, J.
    Goekkurt, E.
    Abdullaev, S.
    Chen, T.
    Lei, M.
    Lonardi, S.
    ANNALS OF ONCOLOGY, 2022, 33 : S250 - S250
  • [10] Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)
    Lenz, H-J. J.
    Van Cutsem, E.
    Limon, M. L.
    Wong, K. Y.
    Hendlisz, A.
    Aglietta, M.
    Garcia-Alfonso, P.
    Neyns, B.
    Luppi, G.
    Cardin, D.
    Dragovich, T.
    Shah, U.
    Atasoy, A.
    Postema, R.
    Boyd, Z.
    Ledeine, J-M.
    Overman, M.
    Lonardi, S.
    ANNALS OF ONCOLOGY, 2018, 29 : 714 - 714
12345